Abstract
e15003Background: IAHCT is more and more recognized in the management of LMCRC. Regarding its anti-angiogenic effect bevacizumab (B) could be considered as a good candidate for IAH treatment. This ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
